DISC-3405
Monoclonal antibody
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Sickle Cell Disease · Phase 1
Company guidance: data expected fourth quarter of 2026 (Disc Medicine, 5 Nov 2026). “We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the fourth quarter of 2026, and plan to explore the role of therapeutic iron restriction in other indications.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06985147 NCT06985147 · Polycythemia Vera Registry: NCT06985147 | 2 | Number of participants with treatment-related adverse events as assessed by CTCAE (Up to 365 days); Incidence of clinically abnormal vital signs (Up to 365 days); Incidence of clinically abnormal physical exam (Up to 365 days); Incidence of clinically abnormal electrocardiograms (Up to 365 days); Incidence of abnormal laboratory test results (Up to 365 days) 2027-07 | In progress: results expected 1 Jul 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Polycythemia Vera: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| DISC-3405: this drug | Phase 2 | Monoclonal antibody | TMPRSS6 (matriptase-2) | not yet graded | No reviewed efficacy summary in this indication | |
| Ropeginterferon Alfa-2b (Besremi) | Approved | Protein / enzyme therapeutic | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Rusfertide | Approved | Peptide | Ferroportin | Reliable signal | NCT05210790: Response in weeks 20 to 32 (Part 1a): rusfertide 76.9% (n=147) vs placebo 32.9% (n=146), odds ratio 6.42 (95% CI 3.81 to 10.80), p<0.0001 (CT.gov posted results). | |
| Ruxolitinib (Jakafi) | Approved | Small molecule | JAK1/2 | Partial signal | NCT01243944: The Percentage of Participants Achieving a Primary Response at Week 32 (32 Weeks): Ruxolitinib 22.7 percentage of participants (95% CI 15.3 to 31.7) | Best Available Therapy 0.9 percentage of participants (95% CI 0 to 4.9) | |
| Givinostat | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow DISC-3405 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.